Success Metrics

Clinical Success Rate
61.5%

Based on 8 completed trials

Completion Rate
62%(8/13)
Active Trials
7(35%)
Results Posted
225%(18 trials)
Terminated
5(25%)

Phase Distribution

Ph phase_2
7
35%
Ph phase_1
12
60%

Phase Distribution

12

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
12(63.2%)
Phase 2Efficacy & side effects
7(36.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

61.5%

8 of 13 finished

Non-Completion Rate

38.5%

5 ended early

Currently Active

7

trials recruiting

Total Trials

20

all time

Status Distribution
Active(7)
Completed(8)
Terminated(5)

Detailed Status

Completed8
Active, not recruiting6
Terminated5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
7
Success Rate
61.5%
Most Advanced
Phase 2

Trials by Phase

Phase 112 (63.2%)
Phase 27 (36.8%)

Trials by Status

recruiting15%
terminated525%
completed840%
active_not_recruiting630%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT05907746Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Active Not Recruiting
NCT03745326Phase 1

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Terminated
NCT04432597Phase 1

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Active Not Recruiting
NCT03663933Phase 2

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active Not Recruiting
NCT02858310Phase 1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed
NCT05371054Phase 1

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Completed
NCT04447027Phase 1

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Completed
NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated
NCT05211336Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active Not Recruiting
NCT03388632Phase 1

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Completed
NCT05035407Phase 1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Terminated
NCT03493945Phase 1

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Completed
NCT05012098Phase 2

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Completed
NCT00923013Phase 2

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Active Not Recruiting
NCT02911142Phase 1

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Active Not Recruiting
NCT03554473Phase 1

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Completed
NCT03092518Phase 2

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Completed
NCT04538378Phase 2

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Terminated
NCT04933617Phase 1

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated
NCT06455488

MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry

Recruiting

All 20 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
20